|
|
|
|
| Symbol(s): |
AMLN |
| Date: |
7-Feb-10 |
| Contributor: |
PriceTarget Research, Inc. |
| Title: |
AMLN has a current Overall Rating of C (Neutral). |
| Document Size: |
7 pages |
| Price: |
$25 |
| Document Type: |
Adobe Acrobat Reader®
Download free Adobe Acrobat Reader® |
|
| Research Reports Premium Services |
| ·
|
Get the full report for $25. |
| ·
|
You will have access to this report for 24 hours. |
|
|
|
|
|
| AMLN has a current Overall Rating of C (Neutral). Power Rating (64) is high; appreciation potential (4) is negative. Relative to the S&P 500 Composite, Amylin Pharmaceuticals Inc has moderate Value characteristics -- its appeal is likely to be to Capital Gain-oriented investors. AMLN is of low investment quality. AMLN's current technical position is very strong. AMLN's Power Rating is 64. Earnings estimate behavior for AMLN has been slightly favorable recently. AMLN's Pharmaceutical...
| | |
|
|
